Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna , Inc. (NASDAQ:MRNA) today confirmed that it has won a tender to supply its mRNA COVID-19 vaccine in the European Union (EU), Norway, and North Macedonia. The agreement, valid for up to four ...

1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through ...

Netflix earnings after the bell drive focus in tech stocks. Dow and S&P climb as optimism over trade policy fuels market ...

The start of a truce prompted celebrations in Gaza, where Hamas militants made a show of force on the streets after 15 months of war. Hours after the first three hostages returned to Israel ...

Moderna has been awarded approximately $590 million ... mRNA technology is the same type that was used in the development of some COVID-19 vaccines. While some vaccines use a weakened or inactive ...

The version of the virus spreading in North America right now has led to only a few serious cases, but concerns have been rising since a death was linked to the virus in Louisiana earlier this month .

Moderna Inc (MRNA) stock saw a decline, ending the day at $33.76 which represents a decrease of $-1.01 or -2.90% from the prior close of $34.77. The stock opened at $34.75 and touched a low of $33.34 ...